The analysis showed that genetic variation in sulfonylureas, GLP-1 analogues, thiazolidinediones, insulin or insulin analogues targets was not associated with ALS (all p > 0.05). The gene discussed is GLP1R; the disease is amyotrophic lateral sclerosis.